Compare MTN & RLAY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MTN | RLAY |
|---|---|---|
| Founded | 1997 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Services-Misc. Amusement & Recreation | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.2B | 1.3B |
| IPO Year | 1997 | 2020 |
| Metric | MTN | RLAY |
|---|---|---|
| Price | $155.13 | $8.09 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 10 | 7 |
| Target Price | ★ $176.50 | $16.00 |
| AVG Volume (30 Days) | 977.1K | ★ 2.1M |
| Earning Date | 12-10-2025 | 11-06-2025 |
| Dividend Yield | ★ 5.62% | N/A |
| EPS Growth | ★ 17.26 | N/A |
| EPS | ★ 7.24 | N/A |
| Revenue | ★ $2,975,101,000.00 | $8,355,000.00 |
| Revenue This Year | $2.69 | $20.47 |
| Revenue Next Year | $3.45 | N/A |
| P/E Ratio | $21.84 | ★ N/A |
| Revenue Growth | ★ 3.06 | N/A |
| 52 Week Low | $129.85 | $1.78 |
| 52 Week High | $194.47 | $9.04 |
| Indicator | MTN | RLAY |
|---|---|---|
| Relative Strength Index (RSI) | 59.76 | 58.26 |
| Support Level | $140.00 | $7.42 |
| Resistance Level | $163.34 | $9.04 |
| Average True Range (ATR) | 4.66 | 0.47 |
| MACD | 2.21 | 0.02 |
| Stochastic Oscillator | 68.93 | 42.54 |
Vail Resorts Inc Bhd is a resorts and casinos company that operates mountain resorts and ski areas. The company has three business segments that include Mountain, Lodging, and Real Estate. The Mountain segment operates numerous ski resort properties that offer a variety of winter and summer activities, such as skiing, snowboarding, snowshoeing, hiking, and mountain biking. The Lodging segment owns and operates hotels and condominiums. The Real Estate segment owns, develops, and leases real estate, typically near its other properties. The company generates the vast majority of its revenue within the United States.
Relay Therapeutics Inc is a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental technologies with the goal of bringing life-changing therapies to patients. the Dynamo platform integrates an array of leading-edge computational and experimental approaches designed to drug-protein targets that have previously been intractable or inadequately addressed. The company is advancing a pipeline of medicine candidates to address targets in precision oncology and genetic disease, including product candidates, RLY-4008, RLY-2608, and GDC-1971 (formerly known as RLY-1971).